Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins [v2; ref status: indexed, http://f1000r.es/4wz]

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...

Full description

Bibliographic Details

Published in:	F1000Research
Main Authors:	Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar, Félix M. Goñi
Format:	Article
Language:	English
Published:	F1000 Research Ltd 2015-01-01
Subjects:	Biomacromolecule-Ligand Interactions Endocrine & Metabolic Pharmacology
Online Access:	http://f1000research.com/articles/2-286/v2